JP2020502153A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502153A5
JP2020502153A5 JP2019532067A JP2019532067A JP2020502153A5 JP 2020502153 A5 JP2020502153 A5 JP 2020502153A5 JP 2019532067 A JP2019532067 A JP 2019532067A JP 2019532067 A JP2019532067 A JP 2019532067A JP 2020502153 A5 JP2020502153 A5 JP 2020502153A5
Authority
JP
Japan
Prior art keywords
plasminogen
obesity
pharmaceutical composition
disease
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019532067A
Other languages
English (en)
Japanese (ja)
Other versions
JP7168990B2 (ja
JP2020502153A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/116562 external-priority patent/WO2018108161A1/zh
Publication of JP2020502153A publication Critical patent/JP2020502153A/ja
Publication of JP2020502153A5 publication Critical patent/JP2020502153A5/ja
Application granted granted Critical
Publication of JP7168990B2 publication Critical patent/JP7168990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019532067A 2016-12-15 2017-12-15 肥満症を予防および治療するための方法および薬物 Active JP7168990B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016110172 2016-12-15
CNPCT/CN2016/110172 2016-12-15
PCT/CN2017/116562 WO2018108161A1 (zh) 2016-12-15 2017-12-15 一种预防和治疗肥胖症的方法和药物

Publications (3)

Publication Number Publication Date
JP2020502153A JP2020502153A (ja) 2020-01-23
JP2020502153A5 true JP2020502153A5 (enExample) 2020-08-13
JP7168990B2 JP7168990B2 (ja) 2022-11-10

Family

ID=62557993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019532067A Active JP7168990B2 (ja) 2016-12-15 2017-12-15 肥満症を予防および治療するための方法および薬物

Country Status (7)

Country Link
US (1) US11207387B2 (enExample)
EP (1) EP3556379B1 (enExample)
JP (1) JP7168990B2 (enExample)
CN (1) CN110114079A (enExample)
CA (1) CA3047181A1 (enExample)
TW (1) TW201829448A (enExample)
WO (1) WO2018108161A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
TW201822805A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
US11219669B2 (en) 2016-12-15 2022-01-11 Talengen International Limited Method for preventing and treating liver fibrosis
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
EP4140498A4 (en) 2020-05-11 2023-11-01 Talengen International Limited Method and drug for treating spinal muscular atrophy

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4245051A (en) 1978-03-30 1981-01-13 Rockefeller University Human serum plasminogen activator
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
DE3515869A1 (de) 1985-05-03 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung optisch aktiver azolderivate
JPS62153224A (ja) 1985-12-27 1987-07-08 Green Cross Corp:The プラスミノゲン製剤
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
JP2764264B2 (ja) 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AU4661493A (en) 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DK125693D0 (enExample) 1993-11-05 1993-11-05 Novo Nordisk As
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
JP2002510209A (ja) 1997-06-26 2002-04-02 カロリンスカ イノベイションズ アクチボラゲット インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン1−5
US7317003B2 (en) 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6465424B1 (en) 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
AU3605800A (en) 1999-02-24 2000-09-14 Henry Ford Health System An anti-angiogenic kringle protein and its mutants
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US20020159992A1 (en) 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
WO2002040510A2 (en) 2000-11-02 2002-05-23 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
ATE415412T1 (de) 2001-08-10 2008-12-15 Novartis Pharma Gmbh Peptide, die atherosklerotische schädigungen binden
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
CN1408431A (zh) 2001-09-21 2003-04-09 北京华兴生生物技术有限公司 治疗与新生血管生成相关疾病的基因工程药物
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
JP2005525798A (ja) 2002-02-06 2005-09-02 トロムスドルフ ゲーエムベーハー ウント コー.カーゲー アルツナイミッテル 微生物内での組み換えタンパク質の生産方法
US20050124036A1 (en) 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
WO2004041155A2 (en) 2002-05-13 2004-05-21 Children's Hospital Los Angeles Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
NZ537006A (en) 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
CN101518535A (zh) 2002-12-06 2009-09-02 法布罗根股份有限公司 脂肪调节
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
WO2005026127A1 (ja) 2003-09-11 2005-03-24 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター-1阻害剤
US20080017694A1 (en) 2003-09-24 2008-01-24 Alexander Schnell Braze Alloy And The Use Of Said Braze Alloy
JP4740531B2 (ja) 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
MXPA06012236A (es) 2004-04-22 2007-01-31 Talecris Biotherapeutics Inc Plasmina modificada en forma recombinante.
US8357147B2 (en) 2005-08-17 2013-01-22 Spinal Restoration, Inc. Method for repairing intervertebral discs
FR2882654B1 (fr) 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
WO2006095713A1 (ja) 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター-1阻害剤
CA2602946A1 (en) 2005-03-22 2006-09-28 Medstar Health, Inc. Delivery systems and methods for diagnosing and treating cardiovascular diseases
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20090123582A1 (en) 2006-03-24 2009-05-14 Akiko Kuwahara Ameliorating Agent for Metabolic Syndrome
WO2008026999A2 (en) 2006-08-28 2008-03-06 Omnio Healer Ab Candidates against infection
WO2008027000A2 (en) 2006-08-28 2008-03-06 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
US20110071107A1 (en) 2006-10-20 2011-03-24 Stephanie K Lynch Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
CN101015686B (zh) 2007-02-06 2010-05-19 中国人民解放军军事医学科学院基础医学研究所 一种溶栓药物增效剂及其制备方法
US20080200387A1 (en) * 2007-02-15 2008-08-21 Hua-Lin Wu Anti-angiogenic protein, composition and use thereof
AR067446A1 (es) 2007-07-11 2009-10-14 Otsuka Pharma Co Ltd Un medicamento para tratar higado graso que comprende cilostazol
RU2010120675A (ru) 2007-10-23 2011-11-27 Инститьют Оф Медисинал Молекьюлар Дизайн, Инк. (Jp) Ингибитор продуцирования pai-1
US20090239868A1 (en) 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
JP5539896B2 (ja) 2007-11-29 2014-07-02 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
CA2711878A1 (en) 2008-01-09 2009-07-16 Intrexon Corporation Therapeutic inhibitors of pai-1 function and methods of their use
US20090208448A1 (en) 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
US20100209350A1 (en) 2008-12-30 2010-08-19 Andreas Pfuetzner Biomarkers for Adipose Tissue Activity
US20120053222A1 (en) 2009-01-23 2012-03-01 Mark Gorrell Novel Metabolic Disease Therapy
US8785473B2 (en) 2009-03-31 2014-07-22 Renascience Co., Ltd. Plasminogen activator inhibitor-1 inhibitor
WO2010125148A2 (en) 2009-04-30 2010-11-04 Catherine Blondel Methods for treating ocular conditions
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
DK2464371T3 (en) 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
CN101628113B (zh) 2009-08-18 2012-01-04 南京农业大学 蚯蚓纤溶酶抗肝纤维化的应用
CN101897925B (zh) 2009-12-16 2015-04-29 成都百康医药工业药理毒理研究院 一种治疗代谢综合症的药物组合物
US20120114652A1 (en) 2010-05-03 2012-05-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
EP2680837A4 (en) 2011-03-03 2015-06-03 Tersus Pharmaceuticals Llc COMPOSITIONS AND METHODS COMPRISING C16: 1N7-PALMITOLATE
CN102199587B (zh) 2011-03-24 2013-06-19 广东药学院 人纤溶酶原功能性突变体及其制备方法和应用
US9029321B2 (en) 2011-03-30 2015-05-12 Board Of Regents Of The University Of Texas Methods and compositions for targeting adipose cells in mammals
CN102188699A (zh) 2011-05-06 2011-09-21 南京农业大学 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用
US20120058537A1 (en) 2011-07-27 2012-03-08 Fereidoun Mahboudi Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップThromboGenics NV プラスミノーゲンおよびプラスミンの変異体
CN102532326B (zh) 2011-11-18 2017-06-09 南京大学 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用
CN103656630B (zh) 2012-09-11 2015-07-08 江苏仁寿药业有限公司 一种提纯动物药材中纤溶酶并制备成中药组合物的方法
WO2014070983A1 (en) 2012-10-31 2014-05-08 The Regents Of The University Of Michigan Plasminogen activator-1 inhibitors and methods of use thereof
WO2014160275A2 (en) 2013-03-14 2014-10-02 Battell Memorial Institute Biomarkers for liver fibrosis
CN104274449A (zh) 2013-07-11 2015-01-14 无锡信达医疗器械有限公司 治疗肥胖症的药物组合物
EA033403B1 (ru) 2013-08-13 2019-10-31 Sanofi Sa Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
TW201734054A (zh) 2013-08-13 2017-10-01 賽諾菲公司 胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
US20160199466A1 (en) 2013-08-20 2016-07-14 Trustees Of Dartmouth College Methods For Treating Tissue Fibrosis
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TW201940191A (zh) 2015-12-18 2019-10-16 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療肝組織損傷及其相關病症的方法
CN115845037A (zh) 2015-12-18 2023-03-28 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
US11338022B2 (en) 2015-12-18 2022-05-24 Talengen International Limited Method for preventing and treating angiocardiopathy
TW201822805A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療

Similar Documents

Publication Publication Date Title
JP2020502156A5 (enExample)
Yang et al. Taurine alleviates trimethylamine N-oxide-induced atherosclerosis by regulating bile acid metabolism in ApoE–/–mice
Amodeo et al. The use of sirolimus in the treatment of giant cystic lymphangioma: Four case reports and update of medical therapy
JP2020502154A5 (enExample)
WO2006014353A3 (en) Glycogen or polysaccharide storage disease treatment method
Lin et al. Enhanced amelioration of high‐fat diet‐induced fatty liver by docosahexaenoic acid and lysine supplementations
JP2017519028A5 (enExample)
Gotloib et al. Experimental model for studies of continuous peritoneal’dialysis in uremic rabbits
Bouquié et al. Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin
Bellmann et al. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases
Peces et al. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex
Westenfelder Does the greater omentum (“policeman of the abdomen”) possess therapeutic utility in CKD?
Sonikian et al. Optimal use of phosphate binders in chronic kidney disease
Yilmaz et al. Rapid response to treatment of heart failure resulting from hypocalcemic cardiomyopathy
Yoshimatsu et al. Percutaneous transcatheter thrombolysis for graft thrombosis after pancreas transplantation
Shiohira et al. Effect of taurine on hemodiafiltration in patients with chronic heart failure
Parikh et al. Liver x receptors: a potential therapeutic target for modulating the atherosclerotic process
EP2559432A1 (en) Means for the prophylaxis and treatment of acute and chronic pancreatitis
JP2019529479A5 (enExample)
Khoo Genetic therapies to lower cholesterol
Maroulis et al. Calciphylaxis: a complication of end-stage renal disease improved by parathyroidectomy
EP3796901A2 (en) Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease
CN101530414B (zh) 化合物酮色林的应用
Masin-Spasovska Fatal fulminant liver failure: case report
Qing-sheng et al. Efficacy and safety of transcatheter chemoembolization of the internal thoracic artery in patients with hepatocellular carcinoma